Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
Majdolen Istaiti, Dafna Frydman, Tama Dinur, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6732-6732
Open Access | Times Cited: 11

Showing 11 citing articles:

Gaucher disease provides a unique window into Parkinson disease pathogenesis
Ellen Hertz, Yu Chen, Ellen Sidransky
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 526-540
Closed Access | Times Cited: 11
Challenges in Gaucher disease: Perspectives from an expert panel
Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, et al.
Molecular Genetics and Metabolism (2025), pp. 109074-109074
Closed Access | Times Cited: 1
Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies
Feda E. Mohamed, Fatma Al‐Jasmi
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
The use of Ambroxol for the treatment of Gaucher disease: A systematic review
Diego Agustín Abelleyra Lastoria, S. Grewal, Derralynn Hughes
eJHaem (2024) Vol. 5, Iss. 1, pp. 206-221
Open Access | Times Cited: 6
Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease
Zuzanna Cyske, Lidia Gaffke, Estera Rintz, et al.
Neurochemistry International (2024) Vol. 178, pp. 105774-105774
Closed Access | Times Cited: 6
Development of Selective Nanomolar Cyclic Peptide Ligands as GBA1 Enzyme Stabilizers
Rebecca E. Katzy, Renier H. P. van Neer, Maria J. Ferraz, et al.
RSC Chemical Biology (2025)
Open Access
Enhancing access to treatment for Gaucher disease in India: The need for indigenous manufacturing
Nidhi Patel, Heta Pandya, Ganesh V. Sangle, et al.
Journal of Biosciences (2024) Vol. 49, Iss. 1
Closed Access | Times Cited: 3
Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent
Neal J. Weinreb, Özlem Göker-Alpan
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2319336-e2319336
Open Access | Times Cited: 5
Functional Analysis of Human GBA1 Missense Mutations in Drosophila: Insights into Gaucher Disease Pathogenesis and Phenotypic Consequences
Aparna Kuppuramalingam, Or Cabasso, Mia Horowitz
Cells (2024) Vol. 13, Iss. 19, pp. 1619-1619
Open Access | Times Cited: 1
Advances in cerebellar disorders: pre-clinical models, therapeutic targets, and challenges
Mario Manto, Jan Cendelín, Michael Strupp, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 10, pp. 965-987
Closed Access | Times Cited: 2
Gaucher Disease: Exploring the Genetic and Clinical Frontiers of a Multifaceted Condition
Carina Toledo Scoparo Barioni, Heloisa Ravaglio, João Pedro Pinto Ferreira Baptista, et al.
International Journal of Health Science (2024) Vol. 4, Iss. 76, pp. 2-17
Open Access
Page 1

Scroll to top